Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors
November 22 2021 - 8:00AM
Business Wire
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company
with a mission to discover, develop and deliver curative therapies
that address the underlying causes of heart disease, today
announced changes to its Board of Directors including the addition
of June Lee, M.D., and the transition of JJ Kang, Ph.D., who will
be stepping down after five years of service.
“We are thrilled to welcome Dr. Lee to our Board at an important
inflection point as we continue our transition towards becoming a
clinical-stage company,” said Faraz Ali, CEO of Tenaya. “Dr. Lee
brings a wealth of highly relevant strategic and operational
development experience to Tenaya and is well-positioned to support
us in our mission to bring new hope to individuals and families
fighting both rare and prevalent forms of heart disease.”
Dr. Lee was most recently Founder and CEO of Esker Therapeutics.
She previously served as Executive Vice President, Chief
Development Officer and Chief Operating Officer of MyoKardia from
2017 to 2020. In this role, Dr. Lee built and led a world-class
global development organization to advance novel therapies for
cardiomyopathies through clinical development. She was previously
also therapeutic area head for early clinical development in
cardiovascular, metabolism, respiratory, and infectious diseases at
Genentech. She currently serves on the Advisory Board for Johns
Hopkins University Center for Therapeutic Translation, serves as a
Board Director for Eledon Pharmaceuticals Inc. and for GenEdit, and
is a member of the Scientific Advisory Board for Foresite Labs. Dr.
Lee completed a Bachelor of Science in chemistry at Johns Hopkins
University, an M.D. at the School of Medicine at the University of
California, Davis, and her clinical training in internal medicine
and pulmonary & critical care at UCLA and UCSF.
“I am very pleased to join Tenaya at such a pivotal time for the
company and for the entire field of precision medicine therapies
for heart disease,” said Dr. Lee. “I look forward to helping Tenaya
realize the full potential of its differentiated science and
capabilities in order to advance potentially transformative
medicines through clinical development and towards future
approvals.”
In addition, Dr. Kang has decided to resign from Tenaya’s Board
to focus on her current role as CEO of Appia Bio and as a Venture
Partner at The Column Group. Dr. Kang helped launch Tenaya in 2016
and has since served as a valued Board member. She also served in
the capacity of interim Tenaya President for the first two years of
the company’s history.
“We cannot thank Dr. Kang enough for her many contributions to
Tenaya over the last five years as a pre-clinical stage company,”
said David Goeddel, Ph.D., Chair of Tenaya’s Board of Directors and
Managing Partner at The Column Group. “We now welcome Dr. Lee to
our Board and look forward to her contributions in support of
Tenaya’s future evolution and growth.”
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a
bold mission: to discover, develop and deliver curative therapies
that address the underlying drivers of heart disease. Founded by
leading cardiovascular scientists from Gladstone Institutes and the
University of Texas Southwestern Medical Center, Tenaya is
developing therapies for rare genetic disorders as well as for more
prevalent heart conditions through three distinct but interrelated
product platforms: Gene Therapy, Cellular Regeneration and
Precision Medicine. For more information, visit
www.tenayatherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in
this press release that are not purely historical are
forward-looking statements. Words such as “expects” and “will,” and
similar expressions are intended to identify forward-looking
statements. Such forward-looking statements include, among other
things, statements by Tenaya’s chief executive officer and its
board members. The forward-looking statements contained herein are
based upon Tenaya’s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. These
forward-looking statements are neither promises nor guarantees and
are subject to a variety of risks and uncertainties, including but
not limited to: risks associated with the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics and operating as an early stage
company; Tenaya’s ability to develop, initiate or complete
preclinical studies and clinical trials, and obtain approvals, for
any of its product candidates; the timing, progress and results of
preclinical studies for TN-201 and Tenaya’s other programs;
Tenaya’s ability to raise any additional funding it will need to
continue to pursue its business and product development plans;
negative impacts of the COVID-19 pandemic on Tenaya’s manufacturing
and operations, including preclinical studies and planned clinical
trials; the timing, scope and likelihood of regulatory filings and
approvals; the potential for any clinical trial results to differ
from preclinical, interim, preliminary, topline or expected
results; Tenaya’s manufacturing, commercialization and marketing
capabilities and strategy; the loss of key scientific or management
personnel; competition in the industry in which Tenaya operates;
Tenaya’s reliance on third parties; Tenaya’s ability to obtain and
maintain intellectual property protection for its product
candidates; general economic and market conditions; and other
risks. Information regarding the foregoing and additional risks may
be found in the section entitled “Risk Factors” in documents that
Tenaya files from time to time with the Securities and Exchange
Commission. These forward-looking statements are made as of the
date of this press release, and Tenaya assumes no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211122005890/en/
Investors Leone Patterson Tenaya Therapeutics
IR@tenayathera.com
Media Kit Rodophele Ten Bridge Communications
krodophele@tenbridgecommunications.com
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Sep 2023 to Sep 2024